Onychomycosis Market Size, Share and Trends 2026 to 2035

Revenue, 2025

USD 4.03 Bn

Forecast Year, 2035

USD 6.41 Bn

CAGR, 2026 - 2035

4.74%

Report Coverage

Global

What is Onychomycosis Market Size in 2026?

The global onychomycosis market size was calculated at USD 4.03 billion in 2025 and is predicted to increase from USD 4.22 billion in 2026 to approximately USD 6.41 billion by 2035, expanding at a CAGR of 4.74% from 2026 to 2035. This market is growing due to the increasing prevalence of diabetes and the growing geriatric population, which directly raises susceptibility to nail fungal infections.

Key Takeaways

• North America dominated the global market in 2025.
• Asia-Pacific is expected to grow at the fastest CAGR between 2026 and 2035.
• By type, the distal subungual onychomycosis segment dominated the market in 2025.
• By type, the white superficial onychomycosis segment is expected to expand at the fastest CAGR between 2026 and 2035.
• By treatment, the topical segment dominated the global market in 2025.
• By treatment, the oral segment is expected to expand at the fastest CAGR between 2026 and 2035.

What Drives the Onychomycosis Market?

The market is driven by the growing prevalence of fungal infections, an aging population with weaker immunity, and increasing diabetes cases. Greater public knowledge of personal hygiene and nail health, alongside the requirement to treat disfigurement and discomfort, is bolstering the need. Increased adoption of advanced, highly effective, and even sometimes minimally invasive treatments, which include new topical and oral antifungal agents. Growing research activities and increasing R&D investments lead to the development of novel drugs and delivery systems for onychomycosis diagnosis and treatment.

How is AI Influencing the Onychomycosis Market?

Onychomycosis is a common fungal nail infection that is a bit challenging to diagnose due to its similarity to a few nail conditions. Accurate identification is important for effective treatment. AI algorithms, mainly convolutional neural networks, are being utilized to analyze clinical, dermoscopic, and even microscopy images. These models can achieve accuracies of over 90%, usually performing better than experienced dermatologists. AI-driven, user-friendly mobile apps are now emerging for remote diagnosis, enabling faster and more accessible healthcare. This is mainly useful in remote or under-resourced areas, allowing early detection.

Apart from diagnosis,Artificial Intelligenceand machine learning (ML) algorithms can play a vital role in suggesting appropriate treatment to patients by analysing their condition. This helps healthcare providers to provide personalized treatment. AI and ML can also derive doses and enable real-time monitoring of patients. They can predict potential adverse effects by analyzing a patient's response to the treatment.

What are the Key Trends Influencing the Onychomycosis Market?

• Rise of Novel Topicals and Improved Formulations: There is a strong shift toward advanced topical treatments, such as lacquers, solutions that provide better nail penetration, reducing the demand for systemic drugs, which usually have side effects. New formulations, such as MOB-015 (Moberg Pharma) and Tavaborole, are gaining traction, with many topical terbinafine solutions showing high efficacy.
• Shift Towards OTC and E-commerce: In developed markets, there is a general trend toward over-the-counter (OTC) access for many topical treatments, with e-commerce platforms remarkably expanding product reach.
• Dominance of Combination Therapy: To combat high recurrence rates and even limited efficacy of single-agent treatments, there is a rising trend toward combining therapies, like oral antifungals with topicals or utilizing laser therapy alongside medication.
• Surge in Elderly and Diabetic Populations: The rising prevalence of diabetes, together with a larger geriatric population, are generally more susceptible to fungal infections, is an important driver for the market.
• Technological Advancements in Devices: The usage of lasers (carbon dioxide and blue light) and even photodynamic therapy (PDT) is gaining praise for treating recalcitrant cases. These non-invasive, device-driven methods are growing due to their ability to treat individuals who cannot tolerate oral medications.

Future Market Outlook

• Expansion in Emerging Markets – Increased knowledge about personal hygiene, along with the aesthetic impact of onychomycosis, coupled with a high prevalence of diabetes and a rising elderly population, is driving the need for treatment in regions such as China, India, and Latin America. Thus, the introduction of high-penetration nail lacquers along with novel topical antifungal agents is increasing, with firms targeting these regions for growth.
• Infrastructure Development- It improved laboratory and manufacturing infrastructure, which supports the development of new, highly effective, nanotechnology-driven products and even sustained-release formulations. The improvement of healthcare infrastructure, mainly in emerging markets, means more specialized dermatology clinics, enhancing access to expert care.

Market Scope

Segmental Insights

Type Insights

Which Type Segment Dominated in the Onychomycosis Market?

The distal subungual onychomycosis segment led the market in 2025 because of the high volume of individuals with distal subungual onychomycosis. Many pharmaceutical firms focus their research and development on this specific kind, leading to a high number of FDA-approved drugs, e.g., efinaconazole, tavaborole, and even new, more effective topical treatments. Further, enhanced diagnostic techniques have now made identifying DSO more accessible, leading to more consistent treatment uptake.

The white superficial onychomycosis segment is expected to grow at the fastest CAGR throughout the forecast period. As the fungi in white superficial onychomycosis state on the surface of the nail plate, they are easily scraped off and even diagnosed, enabling effective treatment with topical antifungal lacquers or creams, which is thus appealing to patients seeking non-systemic options. With developments in topical formulations, for example, nail lacquers, water-soluble treatments, these are generally preferred for mild-to-moderate white superficial onychomycosis because of lower risks of systemic side effects.

Treatment Insights

Why Did the Topical Segment Dominate the Onychomycosis Market?

The topical segment dominated the market in 2025 because the topical treatments, like Jublia and Kerydin, do not enter the bloodstream, lowering the risk of liver damage linked with oral antifungals. Topical formulations are predominantly preferred as they provide targeted intervention. Improved formulations provide better penetration to the nail bed, rising success rates. Increased OTC availability, growing knowledge of nail health, and increasing incidence of toenail infections drive high demand.

The oral segment is expected to grow at the highest CAGR in the upcoming period, due to the superior efficacy compared to topical options, enabling them to effectively treat moderate to severe infections that affect the deeper layers of the nail bed. Oral antifungals provide substantially higher cure rates, usually around 70-90%, compared to topical treatments, which usually struggle to penetrate the nail deeply enough to remove the infection. As oral medications enter the bloodstream, they treat the infection from within, making them more effective for chronic, moderate, and even severe infections.

Regional Insights

North America Onychomycosis Market Size and Growth 2026 to 2035

The North America onychomycosis market size is estimated at USD 1.65 billion in 2025 and is projected to reach approximately USD 2.66 billion by 2035, with a 4.89% CAGR from 2026 to 2035.

What Made North America the Dominant Region in the Onychomycosis Market?

North America dominated the market in 2025. The region's dominance in the market is attributed to being driven by a high prevalence of fungal infections, mainly among aging and diabetic populations, and funded by an advanced healthcare infrastructure. The region boasts solid diagnostic capabilities, high healthcare spending per capita, and even widespread access to both oral and topical antifungal treatments. Strong presence of key pharmaceutical players, like Pfizer, Bausch Health, and Novartis, thus leading to continuous R&D and launch of innovative products.

U.S. Onychomycosis Market Size and Growth 2026 to 2035

The U.S. onychomycosis market size is calculated at USD 1.24 billion in 2025 and is expected to reach nearly USD 2.02 billion in 2035, accelerating at a strong CAGR of 5.00% between 2026 to 2035.

U.S. Market Trends

The U.S. leads the market in North America due to high diabetes prevalence, along with increased awareness of nail health, with the market size anticipated to grow significantly. Companies are targeting R&D for novel, more effective, and shorter-duration treatments, including advanced topical formulations as well as laser therapy, to enhance patient compliance.

What Makes Asia-Pacific the Fastest-Growing Region in the Onychomycosis Market?

Asia-Pacific is expected to grow at the fastest CAGR throughout the forecast period, due to increased awareness about nail health and personal hygiene, which, combined with enhancing healthcare infrastructure, has contributed to higher diagnosis rates. A significant increase in the elderly population and even rising diabetes cases in nations such as China and India have expanded the patient pool.

China Market Trends

China's market is heavily driven by increased healthcare expenses, the adoption of telemedicine for faster, remote diagnosis, and the rise of over-the-counter (OTC) antifungal products in retail pharmacies. Major players such as GSK, Novartis, Pfizer, and local manufacturers are investing in research and development to enhance treatment outcomes.

What Makes Europe a Significant Region in the Onychomycosis Market?

Europe is expected to grow at a significant CAGR throughout the forecast period, driven by the increasing need as pharmaceutical and dermatology firms focus on developing more effective topical, oral, and device-driven antifungal solutions. Growing infection rates among diabetic, elderly, and immunocompromised populations, coupled with rising awareness of early diagnosis and cosmetic nail restoration, are propelling market growth.

UK Market Trends

The growing incidence of diabetes in the UK, with remarkable increases in pre-diabetes cases, is a major driver, as diabetic patients are now highly susceptible to onychomycosis, necessitating consistent and effective treatment. Laser therapy is now gaining traction as a premium, non-invasive, and non-drug option to traditional, long-term pharmaceutical approaches.

Will Latin America Grow in the Onychomycosis Market?

Latin America is expected to grow at a notable CAGR throughout the forecast period. It is driven by high prevalence rates driven by a warm, humid climate, as well as an aging population, and a high incidence of diabetes and HIV, which raise susceptibility to infections. Advancements such as enhanced drug delivery systems, laser therapies, and next-generation formulations, which work with expanding access to dermatology care in many emerging markets, are further accelerating treatment adoption and thus strengthening overall market growth.

Brazil Market Trends

Brazil is positioned as the highest growth market within Latin America for onychomycosis treatments, driven by rising awareness and a large, aging, and diabetic population prone to nail fungus. The market is accepting non-invasive laser treatments such as Nd: YAG and diode lasers for treatment-resistant or severe cases, offering a faster, non-systemic option for patients.

Which Factors Influence the Onychomycosis Market in the Middle East and Africa?

The Middle East and Africa are expected to grow at a considerable CAGR in the upcoming period. The climatic conditions in many areas of the Middle East and Africa are responsible for the growth of fungi, leading to a higher incidence of onychomycosis. There is an increased knowledge regarding personal hygiene and even the aesthetic nature of the infection, mainly in developed markets such as the UAE and Saudi Arabia. This has led to a higher need for treatment.

UAE Market Trends

There is a notable trend towards utilizing non-invasive technologies such as laser treatment, which utilizes selective photothermolysis to kill fungal cells. Topical treatments, like medicated nail lacquers, are the largest and fastest-growing segment in the UAE because of high patient compliance and ease of use. Moreover, specialized dermatology clinics and hospitals are the main providers, offering advanced diagnostic services alongside treatment options.

Onychomycosis Market Value Chain Analysis

• R&D
  The latest research focuses on improving treatment penetration, discovering novel drugs with higher efficacy, and developing new formulations for the treatment of onychomycosis.
  Key Players: Bausch Health Companies, Pfizer, Inc., Novartis, and Bayer AG
• Clinical Trials and Regulatory Approval
  Combination therapies and novel treatment regimens, such as radiotherapy and lasers, are evaluated under clinical trials to assess their safety and efficacy, which are subsequently approved by regulatory agencies.
  Key Players: Pfizer, Oystershell NV, Moberg Pharma AB, FDA, EMA, and NMPA.
• Formulation and Final Dosage Preparation
  This stage involves the development of advanced, high-penetration formulations, including nanoparticles, lacquers, and films, using APIs.
  Key Players: Novartis AG, Galderma Laboratories, and Alembic Pharmaceuticals.
• Distribution to Hospitals, Pharmacies
  Drugs and medical devices are distributed to hospitals and drug stores either directly through manufacturers or through distributors or wholesalers.
  Key Players: Sato Pharmaceutical, Shree Ankira Cosmetics, and Teva Pharmaceuticals
• Patient Support and Services
  Patient support refers to guiding patients about dosage regimens and device usage, while also providing financial assistance.

Onychomycosis Market Companies

• Bausch Health Companies Inc.
• Teva Pharmaceutical Industries Ltd.
• Cipla
• Merck & Co., Inc.GSK plc
• Abbott
• Pfizer Inc
• Bayer AG
• Novartis AG
• Sun Pharmaceutical Industries Ltd.
• Galderma Laboratories
• Moberg Pharma AB
• Sato Pharmaceutical Co., Ltd.

Segments Covered in the Report

By Type

• Distal Subungual Onychomycosis
• White Superficial Onychomycosis
• Proximal Subungual Onychomycosis
• Other Types

By Treatment

• Oral
• Topical
• Others

By Region

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East & Africa